How is pharmaceutical gelatin tested for pharmacopoeia compliance?

Beyond Biopharma | Pharmaceutical Gelatin FAQ

Short answer: Pharmaceutical gelatin is tested for pharmacopoeia compliance by running the tests in the Gelatin monograph of the current edition of the applicable pharmacopoeia, such as USP-NF, EP or JP, each of which defines its own methods and limits for identity, purity, physical properties and microbiology. Because the monographs differ in detail, the same production lot may need separate testing to satisfy each standard, and buyers should request a certificate of analysis prepared against the specific monograph they need.

The three frameworks that matter most

For pharmaceutical use, gelatin is normally tested against the excipient monograph of the pharmacopoeia recognised in the target market: the United States Pharmacopeia-National Formulary (USP-NF) in the United States, the European Pharmacopoeia (EP) in Europe, and the Japanese Pharmacopoeia (JP) in Japan. Each of these contains a Gelatin monograph that defines the tests, the methods and the acceptance criteria for the material. A gelatin lot described simply as 'pharmacopoeia grade' without naming a monograph is not yet a precise statement of compliance.

What a Gelatin monograph typically covers

Although the details differ between frameworks, the Gelatin monographs all cover the same broad areas:

• Identification - tests that confirm the material is gelatin of the declared type.
• Physical properties - gel strength, viscosity, pH, moisture or loss on drying, and appearance of the solution.
• Purity - sulphur dioxide, heavy metals, arsenic, chromium where required, ash or sulphated ash, and related residue tests.
• Microbiology - enumeration of aerobic micro-organisms and absence of specified organisms, tested by the current methods.
• Protein basis - nitrogen or protein content that supports the identity and grade.

Why methods matter as much as limits

The pharmacopoeias are not interchangeable documents: each one defines its own analytical procedures, its own sample preparation and its own pass or fail criteria, and the details change when editions are revised. A result obtained by the USP-NF method is not automatically a result under the EP method, even when the property being measured is the same. This is why compliance is tested 'to' a specific monograph, and why a single certificate can honestly carry different method references for different markets.

How one batch can satisfy several pharmacopoeias

Manufacturers of pharmaceutical gelatin typically release every lot against an internal specification and then run the additional tests needed for the pharmacopoeias their customers require. The same physical lot can therefore be sold as USP-NF compliant in one market and EP or JP compliant in another, provided it has been tested by each monograph's methods and the results meet each set of limits. When you need a material that satisfies more than one standard, state that at the quoting stage so the supplier can confirm the batch has been tested accordingly.

What to ask for in practice

• A COA against the right monograph - request results generated against the specific pharmacopoeia and edition your finished product must meet.
• Current edition results - confirm the certificate reflects the edition in force for your market and filing timeline.
• Supporting documentation - for regulatory filings, ask whether the supplier holds a drug master file or equivalent dossier and how it can be referenced.
• Method details - the certificate should name methods and, where relevant, the edition, so your quality team can verify them.

Related reading

See also how to read a pharmaceutical gelatin specification (COA), what purity tests matter and what microbial limits apply.